June 2009
BioWorld Today;6/11/2009, Vol. 20 Issue 111, p6
This section offers news briefs concerning finance in the biotechnology sector as of June 2009. A three-year $410 million revolving credit facility was obtained by Biovail Corp. from a syndicate of banks. The senior secured convertible notes of Generex Biotechnology Corp. issued in March 2008 to fund oral insulin trials was retired by the company. A $30 million funding was raised by NanoString Technologies Inc. in a two-tranche Series C financing.


Related Articles

  • Financings Roundup.  // BioWorld Today;10/12/2010, Vol. 21 Issue 197, p3 

    This section offers news briefs on financings in the biotechnology industry, including Generex Biotechnology Corp.'s plan to initiate a rights offering of common stock and warrants, Hybrigenics SA's amendment of its agreement with YA Global Master SPV Ltd., and Omeros Corp.'s filing of a 100...

  • Spray On, Insulin Users, Spray On.  // Diabetes Health;Feb/Mar2007, Vol. 16 Issue 1, p29 

    The article announces that Oral-lyn, an insulin spray developed by Generex Biotechnology Corp., has received the 2006 Technology Award for Innovation in the field of diabetic therapies from Frost and Sullivan Co.

  • GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.  // Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p7 

    The article announces that Generex Biotechnology Corp. has received patents in Canada and Argentina. The Canadian Intellectual Property Office has granted Generex a patent that contains process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration,...

  • GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1 

    The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray...

  • GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE.  // Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1 

    The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform....

  • Oral-lyn, the Oral Insulin Spray.  // Diabetes Health;Feb/Mar2010, Vol. 19 Issue 1, p24 

    The article evaluates the Generex Oral-lynâ„¢ insulin spray from Generex Biotechnology Corp.

  • San Antonio Breast Cancer Symposium.  // BioWorld Today;12/9/2011, Vol. 22 Issue 237, p5 

    The article deals with the interim data presented by Generex Biotechnology Corp. at the 2011 San Antonio Breast Cancer Symposium from its continuing Phase II study of the li-Key hybrid-based HER2/neu peptide vaccine in HER2-expressing breast cancer patients.

  • AACR 2012.  // BioWorld Today;4/4/2012, Vol. 23 Issue 65, p7 

    The article reports on Phase II data on AE37, a drug from Generex Biotechnology Corp. designed to increase immune response to human epidermal growth factor receptor 2 (HER2)-expressing cancer cells.

  • Financings Roundup.  // BioWorld Today;2/2/2012, Vol. 23 Issue 13, p4 

    The article reports on the securities purchase agreement of Generex Biotechnology Corp. and on the Series A financing raised by Targovax AS from a Norwegian consortium.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics